ArticleThe journal of allergy and clinical immunology. Global2026
Circulating eosinophils in patients with hypereosinophilic syndrome have heterogeneous immunophenotypes.
Article in The journal of allergy and clinical immunology. Global, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hypereosinophilic syndromes (HES) encompass a heterogeneous group of disorders characterized by blood and/or tissue hypereosinophilia. Despite recent advances, the diagnosis and management of HES remain challenging due to the lack of well-defined biomarkers of disease activity beyond blood eosinophilia. Objectives: We sought to examine blood eosinophil immunophenotypes in patients with HES and determine whether typical markers of eosinophil activation and degranulation correlate with the presence of symptoms and/or treatment response in patients with HES. Methods: Peripheral blood samples were collected from 42 participants (39 patients with HES, 3 healthy donors). Clinical data were extracted by chart review. Surface expression of various eosinophil markers, including CD69, CD62L, CD66b, CD107a, CD107b, CD63, CCR3, CXCR4, CD101, and CD274, were quantified in whole blood by flow cytometry. Results: Absolute eosinophil counts were significantly elevated in symptomatic patients being treated for HES compared to asymptomatic patients being treated for HES. Cell surface expression of degranulation markers, CD107a and CD107b, and immunomodulatory protein CD274, were increased in patients being treated for HES. CCR3, a chemokine receptor for eotaxins, was increased on eosinophils from patients with myeloid HES on imatinib, but not on eosinophils from other patients with HES who are on treatment. Conclusions: These findings enhance our understanding of the heterogeneity of circulating eosinophils in humans and may advance our ability to develop biomarkers of disease activity and effective therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.